Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9193440 | 0.84 | KMT2A (0.57) | KMT2AMEN1MAPTCYP2C9CYP2C19 | |
| SCHEMBL1853406 | 0.81 | MAPT (0.64) | KMT2AGAAMEN1POLBMAPT | |
| SCHEMBL27940498 | 0.80 | KMT2A (0.50) | KMT2AMAPT | |
| SCHEMBL9190580 | 0.80 | MAPT (0.49) | CYP1A2CYP2D6KMT2AMEN1POLB | |
| SCHEMBL9194003 | 0.80 | MAPT (0.49) | CYP1A2CYP2D6KMT2AMEN1POLB | |
| SCHEMBL8985531 | 0.80 | MAPT (0.68) | CYP1A2CYP2D6KMT2AGAAMEN1 | |
| SCHEMBL9195551 | 0.80 | KMT2A (0.52) | CYP1A2CYP2D6KMT2AMEN1POLB | |
| SCHEMBL9192193 | 0.80 | KMT2A (0.49) | CYP1A2CYP2D6MGLLKMT2AGAA | |
| SCHEMBL2678410 | 0.79 | SMN1; SMN2 (0.51) | CYP1A2CYP2D6MGLLKMT2AGAA | |
| SCHEMBL8440899 | 0.78 | KMT2A (0.58) | CYP1A2CYP2D6KMT2AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| EP-0443474-B1 | 1-Phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents | NISSHIN FLOUR MILLING CO (JP) | 1995-08-16 | — | — | EP | disclosed |
| US-5227395-A | ANTI-PLATELET AGGREGATING AGENT | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| US-5140041-A | Cognition activators, for treatment of Alzheimer's disease | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-08-18 | — | — | US | disclosed |
| EP-0443474-A2 | 1-Phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | CYP1A2 432/4885CYP2D6 403/4885MGLL 3491/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | CYP1A2 361/4885CYP2D6 433/4885MGLL 3199/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | CYP1A2 432/4885CYP2D6 403/4885MGLL 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.